Publications by authors named "D P Descamps"

Background: The S147G mutation is associated with high-level resistance to the integrase strand transfer inhibitor (INSTI) elvitegravir. In several poorly documented cases, it was also selected in patients on dolutegravir. Given the widespread use of dolutegravir, further studies of S147G are required.

View Article and Find Full Text PDF

Lenacapavir is the first capsid inhibitor, its use is currently approved for multidrug resistant HIV-1 infection. We report that, despite an initial efficacy of a LEN-containing regimen in patients with multi-drug resistant HIV-2 viruses, virological suppression was not achieved after a year and most patients selected capsid drug-resistance associated mutations.

View Article and Find Full Text PDF

Background: Second-generation integrase strand transfer inhibitors (InSTIs) have a high barrier to resistance and potent antiretroviral activity. They are recommended as first- or second-line (FL and SL) options in two- and three-drug regimens (2DR and 3DR) in international treatment guidelines. However, there are limited real-world data on emerging resistance at the time of virological failure (VF) with these regimens.

View Article and Find Full Text PDF
Article Synopsis
  • * A study involving 30 Togolese female sex workers analyzed 156 HPV genome sequences from cervical and anal swabs, revealing identical infections but varying genetic diversity across HPV types and sites.
  • * Low-risk HPVs showed more mutations induced by APOBEC3 in the E4 and E6 genes compared to high-risk HPVs, which had fewer mutations, suggesting different cancer risk potentials among HPV types.
View Article and Find Full Text PDF